Bridging the "Valley of Death" in Bioscience: Turning Discoveries into Real-World Health Solutions
New Delhi: India has no shortage of scientific talent or discoveries in biosciences. But turning these breakthroughs into solutions that transform lives remains a systemic challenge. Bridging this gap—often called the 'valley of death'—requires more than scientific brilliance. It demands structural reform, aligned incentives, and bold experimentation.
'This is the infamous 'valley of death' in translational research,' says Dr. Anurag Agrawal, Dean of the Trivedi School of Biosciences at
Ashoka University
. 'It's not always a technical issue. Often, people aren't incentivised to go beyond publishing papers.'
To truly cross this chasm, he argues, India must reward translational impact alongside academic publishing. 'We need to evolve institutions so that real-world outcomes matter in career progression,' Dr. Agrawal insists. 'If stepping into translation brings only red tape and no reward, no one will do it.'
Systemic Fixes: Incentives, Incubators, and Innovation Missions
Among his recommendations are streamlining bureaucratic processes, scaling up initiatives like the
Atal Innovation Mission
, and building strong incubators that support not just ideation but implementation.
'These programs are a step in the right direction,' he says, 'but they must be scaled thoughtfully to support productization and field deployment.'
Academia Meets Industry: Building a Bioscience Pipeline
On bridging academia and industry, Dr. Agrawal believes the solution lies in starting young. 'We must ignite passion for innovation early—before students become exam-focused and risk-averse.'
At Ashoka, that vision is taking shape. The university is building an innovation centre physically integrated with the Trivedi School of Biosciences. Undergraduates are encouraged to engage with cutting-edge technologies from day one. 'Biology today is interdisciplinary. AI is the new language of biology,' he declares.
Ashoka has also launched the Lodha Young Genius program, bringing high-school students—some as young as Class 9—face-to-face with leading thinkers like Nobel Laureate Paul Nurse. 'These early sparks can light lifelong fires,' Dr. Agrawal says.
From Rare Disease Breakthroughs to Mainstream Health Innovation
India's foray into genomics gained traction through the diagnosis of pediatric rare diseases using next-generation sequencing (NGS). But Dr. Agrawal sees the future in expanding these capabilities to more prevalent challenges like non-communicable diseases (NCDs), especially cancer.
'In oncology, genomic profiling helps personalise therapies using biomarkers like EGFR or ALK mutations,' he explains. However, such innovations remain largely confined to elite institutions due to cost barriers.
That's changing. Companies like
Karkinos healthcare
and
Strand Life Sciences
, now backed by Reliance, are striving to democratise
genomic diagnostics
. 'If Reliance can do for genomics what it did for telecom with Jio, we may finally see precision oncology become mainstream,' he notes.
Genomic Surveillance: A Public Good, Not a Private Gamble
The COVID-19 pandemic highlighted the critical role of genomic surveillance, but it also exposed gaps. 'If a novel pathogen emerges in a district hospital, are we positioned to catch it early? Not yet,' says Dr. Agrawal.
Platforms like IDSP, IHIP, and INSACOG are steps forward, but genomic surveillance remains overly centralized and research-focused. To be effective, it must be embedded in public health systems, with strong federal coordination.
'Surveillance is a public good,' he stresses. 'It cannot be left to the private sector. The government must lead—especially in a country where health is a state subject but surveillance is centrally governed.'
Precision Medicine—Broadening the Lens
Dr Agrawal urges a more inclusive understanding of
precision medicine
. 'Even a continuous glucose monitor guiding a diabetic's diet is precision health,' he says. In this broader view, AI, mobile tech, and wearable devices can bring personalised care to the masses.
However, a recurring bottleneck remains: access to targeted therapies. 'Genomic diagnostics mean little without affordable access to the corresponding drugs,' he warns. India must align diagnostics with treatment availability, regulatory flexibility, and pricing reforms.
Commenting on what should the National Research Foundation prioritise?, Dr Agarwal informed that the NRF could play a transformative role—if it focuses on people, not just infrastructure. 'Fund curiosity. Fund mentorship. Don't micromanage outcomes,' Dr. Agrawal advises. 'If we invest in passionate researchers and capable institutions, the impact will follow.'
The Road Ahead: From Talent to Translation
India's aspirations in genomics and health innovation are not limited by scientific capability—they're constrained by outdated systems. To unlock the full potential of Indian biosciences, Dr. Agrawal calls for a culture that rewards real-world outcomes, fosters interdisciplinary education, and supports translation at every step.
'Ashoka University may be small, but we can be a lab for the country—where we test bold ideas that scale,' he says. 'India has the talent and the tech. Now, we need to align incentives and invest in the right structures. Only then can we truly democratise health innovation.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
2 days ago
- The Hindu
Is global warming becoming a distraction?
The story so far: A global mean temperature rise of 2°C is enshrined in the Paris Agreement as a safe level of global warming by 2100 with respect to the pre-industrial baseline. This threshold was reduced further to 1.5°C due to the demand from the Alliance of Small Island and Developing States. The climate community has since been trying to quantify climate change and its consequences relative to these warming levels. Unfortunately, the models scientists use for climate projections aren't perfect, which affects the uncertainties in global mean temperature rise estimates. To make predictions for years far beyond 2050, the models need to know the greenhouse gas emissions at the time. Modellers create these figures by imagining energy sources of the future, population growth, and climate actions and policies by then. However, it is anything but easy to simulate societies of the distant future. Thus, projections of global warming in the distant future depend heavily on uncertainties inherent to these speculative scenarios. Is global mean warming important? After 2023 and 2024 turned out to be record warm years, the spectre of crossing the 1.5°C threshold looms large. However, the 2°C warming threshold emerged from a rather arbitrary assumption rooted in the work of economics Nobel laureate William Nordhaus in the 1970s. There has been much debate since as to what this figure represents in real terms, because the two warming levels — 1.5°C and 2°C — aren't particularly special in climate science. In fact, there are uncertainties about the magnitude and/or duration of warming overshoot required for it to be catastrophic. The onslaught of climate-related disasters also makes it clear that any additional warming should be avoided. The exact amount of warming, whether 1.5°C, 1.75°C or 2°C, hardly matters for disaster management and adaptations required today. Did the world really cross 1.5°C? Global temperature estimates are prepared by blending observations and models. Also, multiple groups produce multiple models, which produce multiple estimates — and they are not alike. Two such models of late have claimed the world exceeded 1.5°C of warming in late 2024 whereas one has estimated the world didn't. Be that as it may, the question remains as to whether 2025 will continue to warm or if the rate of warming will drop. Rapid warming events in the past suggest that the rate of warming after sudden jumps tends to decline after a few years. For example, 2024 started out warm following the record warmth of 2023 before the rate of warming dropped. The rate in 2025 has already fallen below that seen in 2024 for the same months. Considering the uncertainties in warming plus irreducible uncertainties in estimating today's temperatures, it is confusing why global mean warming levels remain relevant. Climate adaptation and resilience require large investments. We also need reliable local information to avoid maladapting. Thus, climate mitigation must continue, in fact even accelerate while global mean warming is a distraction we can do without. But with the back-pedalling on climate action in some countries, short-and medium-term predictions, from days to a decade or two, are most urgent now, especially at the hyperlocal scale. What about climate disasters? Climate disasters like heatwaves, floods, and droughts are becoming more protracted, frequent, and intense. Insurance losses, number of lives, and number of livelihoods lost worldwide are rising year on year. These disasters are a reminder that unless researchers can pinpoint which disaster is likely to occur where and with sufficient actionable lead time — for example, a few days to few weeks for most extreme events — focusing on global mean warming can be wasteful, if not misguided. Early-warning systems and disaster management are becoming better overall and global plans under the UN, such as Early Warnings for All, promise to ensure poorer countries are not left out. If we are to manage day-to-day crises better even as the risks of climate hazards increase, we also need predictions at the decadal timescale to allow countries to plan ahead for adaptation and resilience. This in turn demands that we focus on tracking disasters, preparedness, management and recovery. The earth's tropics are a hotspot of climate change's consequences since they are warmer to begin with. So catastrophic floods outside the tropics, such as those in Valencia in 2024, are a stark reminder that good early warnings are worthless unless they are actionable up to the last mile. It has become common in the wake of disasters for some research groups to claim it was caused by global warming. However, we need to focus on more important questions: whether a given forecast was accurate and whether all disaster management agencies on the ground received it in time. If a forecast fails, they need to be recorded and documented as such; if a forecast was accurate but the government failed to prepare for it in time, the points of failure must be quickly identified and corrected. This acknowledges that climate risk and uncertainties are never zero, that risks are not predestined, and that we have agency in mitigating them. Raghu Murtugudde is retired professor, IIT Bombay, and emeritus professor, University of Maryland.
NDTV
4 days ago
- NDTV
Researchers Eyeing Options Beyond US Can Look To This Country
With former US President Donald Trump back in power, the American research community is facing renewed uncertainty. Visa cancellations, abrupt funding cuts, and restrictive policies are pushing scientists and researchers to seek opportunities elsewhere. Amid this exodus, Germany has stepped in as a welcoming alternative-especially through its Max Planck Society. The Max Planck Society, one of the world's leading research networks, has seen a huge surge in applications from US-based researchers for its Spring 2025 intake. Notably, 81 women scientists from the US have applied this year, up from just 25 last year. The rise in applications from the US contrasts with stable numbers from other parts of the world, signalling a significant shift in researcher sentiment. Max Planck Society President Patrick Cramer revealed that nearly half of these new applicants are affiliated with leading US institutions such as Harvard University, Stanford University, MIT, the National Institutes of Health (NIH), and the University of California system. Funded by the German government, the society comprises 84 research institutes and operates on an annual budget of 2 billion euros. It currently hosts 39 Nobel laureates, and 20 new researcher positions are now open. The exodus of researchers is largely linked to the Trump administration's crackdown on international scholars. A controversial directive sought to ban institutions like Harvard from admitting foreign students. Although a federal court has temporarily blocked this move, the uncertainty has already triggered panic in academic circles. The broader global education and research community has taken notice. High-profile scholars such as Yale historian Timothy Snyder have resigned in protest and relocated to institutions abroad. Anticipating this wave of displaced researchers, Germany has launched a national initiative called "1000 Brains" to expand its research infrastructure and absorb global talent.
New Indian Express
4 days ago
- New Indian Express
‘Covid needs more surveillance than common cold, cough'
Former director of the Institute of Genomics and Integrative Biology and ex-chair of the WHO technical advisory group for viral evolution, Dr Anurag Agarwal, says that India will be able to ride the current Covid-19 surge without increased hospitalisation or deaths. Currently the Dean of BioSciences and Health Research at the Trivedi School of Biosciences, Ashoka University, and head of the Koita Centre for Digital Health, he spoke with Kavita Bajeli-Datt about the evolution and surveillance of Covid. Excerpts: India is again experiencing a surge in Covid-19 cases. How do you view the latest surge, coming after a brief pause? Globally, there have been many such surges since the initial Omicron wave. These have all been with descendants of Omicron, and no new variant of concern has emerged. The risk to public health has been low due to the change in the virus and, more importantly, sufficient immunity to protect against severe disease. I expect this surge to follow the same pattern as the rise in infections, with little change in hospitalisations or deaths. So, we should ride this wave, too. Do we need to start wearing masks, especially those living in Kerala, Maharashtra and Delhi, which are the top contributors? It is always good to avoid infections, and wearing masks in crowded places with poor ventilation is always a good idea, especially for high-risk individuals, such as the elderly. Whichever place tests more seems to be the highest contributor.
